Skip to content

Annovis Bio, Inc.

ANVS

CIK 0001477845 · Pharmaceutical Preparations · NYSE

  • QR Pharma, Inc. (until 2019-03-15)
← back to feed
Revenue (TTM)
$0
Q1 May 2026
Net Income (TTM)
−$36.63M
−17.3% YoY Q1 May 2026
EPS Diluted (TTM)
−$1.64
+39.4% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
—
Q1 May 2026
Cash
$14.22M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
34.65M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings